SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility

Abstract Introduction Soon after the onset of the SARS-CoV-2 pandemic, viral screening by nasopharyngeal swab became mandatory for allogeneic hematopoietic stem cell (HSC) donor eligibility. Methods We described our monocenter experience with allogeneic HSC donors from February 1 to the October 31, 2020 to verify whether the introduction of SARS-CoV-2 screening altered the donor eligibility and/or entailed a prolongation of the evaluation process. Results A total of 21 allogeneic HSC donors were screened during the above-mentioned period upon request by the local transplant physicians or by the Italian Bone Marrow Donor Registry; among the HSC donors (n = 17) who completed the eligibility process and further received the nasopharyngeal swab, all but one were negative for the presence of SARS-CoV-2. The positive donor remained asymptomatic for the whole duration of the infection, which lasted six weeks. However, he was temporarily excluded from donation. The median duration of the evaluation process was not significantly different, compared to the same period of 2019 (p-value = 0.11). Conclusion The mandatory SARS-CoV-2 screening in allogeneic HSC donors allowed for the detection of 6% positivity in this monocenter series over a 9-month period. Despite the inconvenience of this unexpected non-eligibility, the exclusion of a SARS-CoV-2 positive donor represented an important safety measure for the donor, with respect to a new and still partially unknown virus. The screening did not alter the length of the donor evaluation and thus, did not cause a delay in the eligibility process.

Saved in:
Bibliographic Details
Main Authors: Crocchiolo,Roberto, Alfarano,Francesco, Volpato,Elisabetta, Pugliano,Mariateresa, Cuppari,Irene, Mazza,Anna Maria, Bellio,Laura, Fanti,Diana, Vismara,Chiara, Scaglione,Francesco, Sacchi,Nicoletta, Pollichieni,Simona, Mele,Lia, Diral,Elisa, Grillo,Giovanni, Rossini,Silvano
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) 2022
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000100013
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2531-13792022000100013
record_format ojs
spelling oai:scielo:S2531-137920220001000132022-03-16SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibilityCrocchiolo,RobertoAlfarano,FrancescoVolpato,ElisabettaPugliano,MariateresaCuppari,IreneMazza,Anna MariaBellio,LauraFanti,DianaVismara,ChiaraScaglione,FrancescoSacchi,NicolettaPollichieni,SimonaMele,LiaDiral,ElisaGrillo,GiovanniRossini,Silvano Sars-cov-2 Hematopoietic stem cells Donors Eligibility Screening Abstract Introduction Soon after the onset of the SARS-CoV-2 pandemic, viral screening by nasopharyngeal swab became mandatory for allogeneic hematopoietic stem cell (HSC) donor eligibility. Methods We described our monocenter experience with allogeneic HSC donors from February 1 to the October 31, 2020 to verify whether the introduction of SARS-CoV-2 screening altered the donor eligibility and/or entailed a prolongation of the evaluation process. Results A total of 21 allogeneic HSC donors were screened during the above-mentioned period upon request by the local transplant physicians or by the Italian Bone Marrow Donor Registry; among the HSC donors (n = 17) who completed the eligibility process and further received the nasopharyngeal swab, all but one were negative for the presence of SARS-CoV-2. The positive donor remained asymptomatic for the whole duration of the infection, which lasted six weeks. However, he was temporarily excluded from donation. The median duration of the evaluation process was not significantly different, compared to the same period of 2019 (p-value = 0.11). Conclusion The mandatory SARS-CoV-2 screening in allogeneic HSC donors allowed for the detection of 6% positivity in this monocenter series over a 9-month period. Despite the inconvenience of this unexpected non-eligibility, the exclusion of a SARS-CoV-2 positive donor represented an important safety measure for the donor, with respect to a new and still partially unknown virus. The screening did not alter the length of the donor evaluation and thus, did not cause a delay in the eligibility process.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)Hematology, Transfusion and Cell Therapy v.44 n.1 20222022-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000100013en10.1016/j.htct.2021.09.017
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Crocchiolo,Roberto
Alfarano,Francesco
Volpato,Elisabetta
Pugliano,Mariateresa
Cuppari,Irene
Mazza,Anna Maria
Bellio,Laura
Fanti,Diana
Vismara,Chiara
Scaglione,Francesco
Sacchi,Nicoletta
Pollichieni,Simona
Mele,Lia
Diral,Elisa
Grillo,Giovanni
Rossini,Silvano
spellingShingle Crocchiolo,Roberto
Alfarano,Francesco
Volpato,Elisabetta
Pugliano,Mariateresa
Cuppari,Irene
Mazza,Anna Maria
Bellio,Laura
Fanti,Diana
Vismara,Chiara
Scaglione,Francesco
Sacchi,Nicoletta
Pollichieni,Simona
Mele,Lia
Diral,Elisa
Grillo,Giovanni
Rossini,Silvano
SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility
author_facet Crocchiolo,Roberto
Alfarano,Francesco
Volpato,Elisabetta
Pugliano,Mariateresa
Cuppari,Irene
Mazza,Anna Maria
Bellio,Laura
Fanti,Diana
Vismara,Chiara
Scaglione,Francesco
Sacchi,Nicoletta
Pollichieni,Simona
Mele,Lia
Diral,Elisa
Grillo,Giovanni
Rossini,Silvano
author_sort Crocchiolo,Roberto
title SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility
title_short SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility
title_full SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility
title_fullStr SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility
title_full_unstemmed SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility
title_sort sars-cov-2 screening in allogeneic hematopoietic stem cell donors: implications for the evaluation process and eligibility
description Abstract Introduction Soon after the onset of the SARS-CoV-2 pandemic, viral screening by nasopharyngeal swab became mandatory for allogeneic hematopoietic stem cell (HSC) donor eligibility. Methods We described our monocenter experience with allogeneic HSC donors from February 1 to the October 31, 2020 to verify whether the introduction of SARS-CoV-2 screening altered the donor eligibility and/or entailed a prolongation of the evaluation process. Results A total of 21 allogeneic HSC donors were screened during the above-mentioned period upon request by the local transplant physicians or by the Italian Bone Marrow Donor Registry; among the HSC donors (n = 17) who completed the eligibility process and further received the nasopharyngeal swab, all but one were negative for the presence of SARS-CoV-2. The positive donor remained asymptomatic for the whole duration of the infection, which lasted six weeks. However, he was temporarily excluded from donation. The median duration of the evaluation process was not significantly different, compared to the same period of 2019 (p-value = 0.11). Conclusion The mandatory SARS-CoV-2 screening in allogeneic HSC donors allowed for the detection of 6% positivity in this monocenter series over a 9-month period. Despite the inconvenience of this unexpected non-eligibility, the exclusion of a SARS-CoV-2 positive donor represented an important safety measure for the donor, with respect to a new and still partially unknown virus. The screening did not alter the length of the donor evaluation and thus, did not cause a delay in the eligibility process.
publisher Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
publishDate 2022
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000100013
work_keys_str_mv AT crocchioloroberto sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT alfaranofrancesco sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT volpatoelisabetta sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT puglianomariateresa sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT cuppariirene sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT mazzaannamaria sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT belliolaura sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT fantidiana sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT vismarachiara sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT scaglionefrancesco sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT sacchinicoletta sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT pollichienisimona sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT melelia sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT diralelisa sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT grillogiovanni sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
AT rossinisilvano sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility
_version_ 1756442080101531648